

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer to sell or solicitation of an offer to buy, to purchase or subscribe for securities nor shall there be any sale of Offer Shares in the United States or in any other jurisdictions in which such offer or solicitation would be unlawful. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “**U.S. Securities Act**”) or any state securities law of the United States. The securities may not be offered, sold, pledged, or transferred within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities Act (“**Regulation S**”)) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offering of securities in the United States. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company. This announcement is not a prospectus. Potential investors should read the prospectus dated June 15, 2026 (the “**Prospectus**”) of Shaanxi Micot Pharmaceutical Technology Co., Ltd. (陝西麥科奧特醫藥科技股份有限公司) (the “**Company**”) carefully for detailed information about the Company and the Global Offering before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Global Offering should be taken solely in reliance on the information in the Prospectus.*

*Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.*

*In connection with the Global Offering, CCB International Capital Limited, as the stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it, may, to the extent permitted by applicable laws of Hong Kong or elsewhere, over-allocate or effect transactions with a view to stabilizing or maintaining the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager (its affiliates or any person acting for it) to conduct any such stabilizing action. Such stabilizing action, if taken, (a) will be conducted at the absolute discretion of the Stabilizing Manager (its affiliates or any person acting for it) and in what the Stabilizing Manager reasonably regards as the best interest of the Company, (b) may be discontinued at any time and (c) is required to be brought to an end within 30 days of the last day for lodging applications under the Hong Kong Public Offering. Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).*

*Potential investors should be aware that stabilizing action cannot be taken to support the price of the Shares for longer than the stabilization period will begin on the Listing Date, and is expected to expire on Saturday, July 18, 2026, the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.*

*The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to the terms and conditions set out in the Prospectus. The Hong Kong Offer Shares will not be offered to any person who is outside Hong Kong and/or not resident in Hong Kong. Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement upon the occurrence of any of the events set out in the paragraph headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be Wednesday, June 24, 2026).*



## **Shaanxi Micot Pharmaceutical Technology Co., Ltd.**

### **陝西麥科奧特醫藥科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

#### **GLOBAL OFFERING**

**Number of Offer Shares under the : 58,054,400 H Shares**  
**Global Offering**  
**Number of Hong Kong Offer Shares : 5,805,600 H Shares**  
**Number of International Offer Shares : 52,248,800 H Shares**  
**Final Offer Price : HK\$18.20 per H Share, plus brokerage**  
**of 1.0%, SFC transaction levy of**  
**0.0027%, AFRC transaction levy of**  
**0.00015% and the Stock Exchange**  
**trading fee of 0.00565% (payable in full**  
**on application in Hong Kong Dollars,**  
**subject to refund)**  
**Nominal value : RMB0.02 per H Share**  
**Stock code : 2335**

***Joint Sponsors, Overall Coordinators, Sponsor-Overall Coordinators,  
Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers***



#### ***Joint Bookrunners and Joint Lead Managers***



**Shaanxi Micot Pharmaceutical Technology Co., Ltd.**  
**陝西麥科奧特醫藥科技股份有限公司**

**ANNOUNCEMENT OF ALLOTMENT RESULTS**

**Warning: In view of high concentration of shareholding in a small number of H Shareholders, Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.**

**SUMMARY**

**Company information**

<b>Stock code</b>	2335
<b>Stock short name</b>	MICOT PHARMA-B
<b>Dealings commencement date</b>	June 24, 2026 *

\* see note at the end of the announcement

**Price Information**

<b>Final Offer Price</b>	HK\$18.20
--------------------------	-----------

**Offer Shares and Share Capital**

<b>Number of Offer Shares</b>	58,054,400
<b>Final number of Offer Shares in Hong Kong Public Offering</b>	5,805,600
<b>Final number of Offer Shares in International Offering</b>	52,248,800
<b>Number of issued Shares upon Listing</b>	331,740,350

**Over-allocation**

<b>No. of Offer Shares over-allocated</b>	0
<i>There has been no over-allocation of Offer Shares in the International Offering. Therefore, the Over-allotment Option will not be exercised and will lapse upon Listing.</i>	

**Proceeds**

<b>Gross proceeds (Note)</b>	HK\$1,056.6 million
<b>Less: Estimated listing expenses payable based on Final Offer Price</b>	HK\$67.3 million
<b>Net proceeds</b>	HK\$989.3 million

*Note: Gross proceeds refer to the amount which the Company is entitled to receive. For details of the use of proceeds, please refer to the section headed “Future Plans and Use of Proceeds” of the Prospectus.*

## **ALLOTMENT RESULTS DETAILS**

### ***HONG KONG PUBLIC OFFERING***

<b>No. of valid applications</b>	153,832
<b>No. of successful applications</b>	22,665
<b>Subscription level</b>	1,181.46 times
<b>Claw-back triggered</b>	N/A
<b>No. of Offer Shares initially available under the Hong Kong Public Offering</b>	5,805,600
<b>No. of Offer Shares reallocated from the International Offering</b>	0
<b>Final no. of Offer Shares under the Hong Kong Public Offering</b>	5,805,600
<b>% of Offer Shares under the Hong Kong Public Offering to the Global Offering</b>	10%

*Note: For details of the final allocation of H Shares to the Hong Kong Public Offering, investors can refer to [www.hkeipo.hk/IPOResult](http://www.hkeipo.hk/IPOResult) to perform a search by identification document number or [www.hkeipo.hk/IPOResult](http://www.hkeipo.hk/IPOResult) for the full list of allottees.*

### ***INTERNATIONAL OFFERING***

<b>No. of places</b>	73
<b>Subscription Level</b>	2.52 times
<b>No. of Offer Shares initially available under the International Offering</b>	52,248,800
<b>No. of Offer Shares reallocated to the Hong Kong Public Offering</b>	0
<b>Final no. of Offer Shares under the International Offering</b>	52,248,800
<b>% of Offer Shares under the International Offering to the Global Offering</b>	90%

*The Directors confirm that, to the best of their knowledge, information and belief, save for consent under paragraph 1C(2) of Appendix F1 to the Listing Rules granted by the Stock Exchange to permit Qiyuan Hong Kong, a close associates of Existing Shareholders, to*

participate in the Global Offering as a cornerstone investor subject to certain conditions, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of H Shares registered in his/her/its name or otherwise held by him/her/it.

***The placees in the International Offering include the following:***

***Cornerstone Investors***

<i>Investor</i> <sup>note 1</sup>	<i>TNo. of Offer Shares allocated</i>	<i>% of Offer Shares after the Global Offering</i>	<i>% of total issued share capital in the Company after the Global Offering</i>	<i>Existing shareholders or their close associates</i>
Qiyuan Hong Kong <sup>note 2</sup>	18,756,200	32.31%	5.65%	YES
Everest Medicine	5,494,400	9.46%	1.66%	No
Summit Capital	430,400	0.74%	0.13%	No
<b>Total</b>	<b>24,681,000</b>	<b>42.51%</b>	<b>7.44%</b>	
<p><i>Notes:</i></p> <ol style="list-style-type: none"> <li><i>For further details of the Cornerstone Investors, please refer to the section headed “Cornerstone Investors” in the Prospectus.</i></li> <li><i>As disclosed in the Prospectus, as Qiyuan Hong Kong is ultimately controlled by government bodies of Shaanxi Province, it is a close associate of existing Shareholders of the Company. The Company has sought, and the Stock Exchange has given, a consent under paragraph 1C(2) of Appendix F1 to the Listing Rules to permit Qiyuan Hong Kong to participate in the Global Offering as a cornerstone investor subject to certain conditions. For further details of the abovementioned consent, please refer to the section headed “Waivers from Strict Compliance with the Listing Rules and Exemption from Strict Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance” in the Prospectus and “Others/Additional Information” in this announcement for details.</i></li> </ol>				

***Allottee with Waiver/Consent Obtained***

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares after the Global Offering</i> <sup>Note 4</sup>	<i>% of total issued share capital in the Company after the Global Offering</i> <sup>Note 5</sup>	<i>Relationship</i>
<b><i>Allottee with consent under paragraph 1C(2) of the Placing Guidelines under Chapters 2.3 and 4.15 of the Guide in relation to allocation of Offer Shares to a close associate of existing Shareholders</i></b> <sup>Note 1</sup>				
Qiyuan Hong Kong	18,756,200	32.31%	5.65%	A close associate of existing Shareholders
<p><i>Notes:</i></p> <p>1. The Stock Exchange has given a consent under paragraph 1C(2) of the Placing Guidelines and Chapters 2.3 and 4.15 of Guide to permit Offer Shares to be placed to the above placee who is a close associate of existing Shareholders. Please refer to the section headed “Others/Additional Information” in this announcement.</p>				

## LOCK-UP UNDERTAKINGS

### Cornerstone Investors

<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of total issued share capital in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i> <sup>Note 1</sup>
Qiyuan Hong Kong	18,756,200	6.70%	5.65%	December 23, 2026
Everest Medicine	5,494,400	1.96%	1.66%	December 23, 2026
Summit Capital	430,400	0.15%	0.13%	December 23, 2026
<b>Total</b>	<b>24,681,000</b>	<b>8.81 %</b>	<b>7.44 %</b>	
Notes:				
1. In accordance with the relevant cornerstone investment agreements, the required lock-up ends on December 23, 2026. The Cornerstone Investors will cease to be prohibited from disposing of or transferring H Shares subscribed pursuant to the relevant cornerstone investment agreements after the indicated date.				

### Controlling Shareholders

<i>Name</i> <sup>Note 1</sup>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of total issued share capital in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i> <sup>Note 2</sup>
Dr. Wang Bing	111,000,000	66,600,000	23.78%	33.46%	June 23, 2027
Dr. Wang Mei	18,060,050	18,060,050	6.45%	5.44%	June 23, 2027
Xi'an Zhongrui	15,000,000	15,000,000	5.36%	4.52%	June 23, 2027
<b>Total</b>	<b>144,060,050</b>	<b>99,660,050</b>	<b>35.58%</b>	<b>43.43%</b>	
Notes:					
1. As of the date of this announcement, Dr. Wang Bing (王冰), Dr. Wang Mei (王梅) and Xi'an Zhongrui directly held 40.56%, 6.60% and 5.48% of the interest in our Company, respectively. Dr. Wang Bing and Dr. Wang Mei are spouses. Dr. Wang Mei and Dr. Wang Bing held 99.00% and 1.00% of the equity interest, respectively, in Zhongrui Zekang, which acts as the general partner of Xi'an Zhongrui. Xi'an Zhongrui directly held 5.48% of the equity interest in the Company, such that Dr. Wang Mei and Dr. Wang Bing are deemed to be the beneficial owners of the 5.48% equity interest in the Company held by Xi'an Zhongrui. Therefore, Dr. Wang Bing, Dr. Wang Mei, Xi'an Zhongrui and Zhongrui Zekang will be regarded as our Controlling Shareholders under the Listing Rules before the Listing. For further details, please refer to the section headed "Relationship with our Controlling Shareholders" in the Prospectus.					
2. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law. The required lock-up for the Controlling Shareholders ends on June 23, 2027, being twelve months following the Listing Date. Pursuant to Rule 10.07 of the Listing Rules, each of the Controlling Shareholders (namely Dr. Wang Bing, Dr. Wang Mei, Xi'an Zhongrui and Zhongrui Zekang) has undertaken to the Stock Exchange and the Company that, he, she or it shall comply with the applicable lockup requirements. For further details, please refer to the section headed "Underwriting — Undertakings to the Stock Exchange Pursuant to the Listing Rules — Undertakings by our Controlling Shareholders" in the Prospectus.					

## Other Existing Shareholders

Name	Number of Shares held in the Company subject to lock-up undertakings upon Listing	Number of H Shares held in the Company subject to lock-up undertakings upon Listing	% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing	% of total issued share capital in the Company subject to lock-up undertakings upon Listing	Last day subject to the lock-up undertakings <sup>Note 1</sup>
<b>The People's Government of Shaanxi Province</b>					
Junying Growth	3,982,350	3,982,350	1.42%	1.20%	June 23, 2027
Listing Reserve Fund	3,631,750	3,631,750	1.30%	1.09%	June 23, 2027
Junying Jiacheng	2,017,650	2,017,650	0.72%	0.61%	June 23, 2027
Xi'an Huiyu	907,950	907,950	0.32%	0.27%	June 23, 2027
Shaanxi Innovation Relay	4,153,850	–	–	1.25%	–
Shaanxi Jingang	3,115,400	–	–	0.94%	–
New Materials Fund	6,000,000	6,000,000	2.14%	1.81%	June 23, 2027
<b>Other Shareholders</b>					
Suzhou Mainiv	27,333,350	27,333,350	9.76%	8.24%	June 23, 2027
Beta Achieve	17,733,350	17,733,350	6.33%	5.35%	June 23, 2027
Linhai Qize	14,382,650	14,382,650	5.14%	4.34%	June 23, 2027
Huaxin Pharmaceutical Venture Capital	7,776,650	7,776,650	2.78%	2.34%	June 23, 2027
Suzhou Rongsheng	6,833,350	6,833,350	2.44%	2.06%	June 23, 2027
Xi'an Tongshang	5,939,950	5,939,950	2.12%	1.79%	June 23, 2027
Fengchuan Hongbo	5,125,000	5,125,000	1.83%	1.54%	June 23, 2027
Jingcheng Daxing	5,075,100	5,075,100	1.81%	1.53%	June 23, 2027
Tangxing Technology	4,780,200	4,780,200	1.71%	1.44%	June 23, 2027
Shanjin Runji	3,947,750	3,947,750	1.41%	1.19%	June 23, 2027
Hainan Wanfeng	1,361,900	1,361,900	0.49%	0.41%	June 23, 2027
Yinyun Heman	907,950	907,950	0.32%	0.27%	June 23, 2027
Hangzhou Quandewang	907,950	907,950	0.32%	0.27%	June 23, 2027
Hainan Ruizheng	907,950	907,950	0.32%	0.27%	June 23, 2027



<i>Name</i>	<i>Number of Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of total issued share capital in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings <sup>Note 1</sup></i>
Maicheng Century	1,557,700	1,557,700	0.56%	0.47%	June 23, 2027
Jinan Liuji	1,246,150	1,246,150	0.44%	0.38%	June 23, 2027
<b>Total</b>	<b>129,625,900</b>	<b>122,356,650</b>	<b>43.69%</b>	<b>39.07%</b>	
<i>Notes:</i>					
1. Under the applicable PRC laws, all existing Shareholders are subject to a lockup period of twelve months following the Listing Date.					

### ***PLACEE CONCENTRATION ANALYSIS***

<b>Placees*</b>	<b>Number of H Shares allotted</b>	<b>Allotment as % of International Offering</b>	<b>Allotment as % of total Offer Shares</b>	<b>Number of H Shares held upon Listing</b>	<b>% of total issued share capital upon Listing</b>
Top 1	18,756,200	35.90%	32.31%	18,756,200	5.65%
Top 5	39,640,000	75.87%	68.28%	39,640,000	11.95%
Top 10	45,269,000	86.64%	77.98%	45,269,000	13.65%
Top 25	51,790,600	99.12%	89.21%	51,790,600	15.61%

*Note:*

\* Ranking of placees is based on the number of H Shares allotted to the placees.

## ***H SHAREHOLDER CONCENTRATION ANALYSIS***

<b>H Shareholders*</b>	<b>Number of H Shares allotted</b>	<b>Allotment as % of International Offering</b>	<b>Allotment as % of total Offer Shares</b>	<b>Number of H Shares held upon Listing</b>	<b>% of total issued H share capital upon Listing</b>	<b>Number of Shares held upon Listing</b>
Top 1	0	NA	NA	99,660,050	35.58%	144,060,050
Top 5	18,756,000	35.90%	32.31%	194,405,300	69.41%	246,074,550
Top 10	33,204,000	63.55%	57.20%	229,403,650	81.91%	281,072,900
Top 25	44,574,800	85.31%	76.78%	265,683,550	94.86%	317,352,800

*Note:*

\* *Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.*

## ***SHAREHOLDER CONCENTRATION ANALYSIS***

<b>Shareholders*</b>	<b>Number of H Shares allotted</b>	<b>Allotment as % of International Offering</b>	<b>Allotment as % of total Offer Shares</b>	<b>Number of H Shares held upon Listing</b>	<b>Number of Shares held upon Listing</b>	<b>% of total issued share capital upon Listing</b>
Top 1	0	NA	NA	99,660,050	144,060,050	43.43%
Top 5	18,756,200	35.90%	32.31%	194,405,300	246,074,550	73.18%
Top 10	33,204,600	63.55%	57.20%	229,403,650	281,072,900	84.73%
Top 25	44,574,800	85.31%	76.78%	265,683,550	317,352,800	95.66%

*Note:*

\* *Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholders upon Listing.*

## ***BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING***

Subject to the satisfaction of the conditions set out in the Prospectus, a total of 153,832 valid applications made by the public will be conditionally allocated on the basis set out below:

### **Pool A**

<b>Number of H Shares applied for</b>	<b>Number of valid applications</b>	<b>Basis of allocation/ballot</b>	<b>Approximate percentage allotted of the total number of H Shares applied for</b>
200	44,060	1,322 out of 44,060 applicants to receive 200 H Shares	3.00%
400	24,701	976 out of 24,701 applicants to receive 200 H Shares	1.98%
600	4,048	188 out of 4,048 applicants to receive 200 H Shares	1.55%
800	2,703	141 out of 2,703 applicants to receive 200 H Shares	1.30%
1,000	3,083	175 out of 3,083 applicants to receive 200 H Shares	1.14%
1,200	1,918	118 out of 1,918 applicants to receive 200 H Shares	1.03%
1,400	1,344	88 out of 1,344 applicants to receive 200 H Shares	0.94%
1,600	1,425	98 out of 1,425 applicants to receive 200 H Shares	0.86%
1,800	1,500	108 out of 1,500 applicants to receive 200 H Shares	0.80%
2,000	12,982	970 out of 12,982 applicants to receive 200 H Shares	0.75%
3,000	3,436	302 out of 3,436 applicants to receive 200 H Shares	0.59%
4,000	4,863	479 out of 4,863 applicants to receive 200 H Shares	0.49%
5,000	1,990	214 out of 1,990 applicants to receive 200 H Shares	0.43%
6,000	1,481	171 out of 1,481 applicants to receive 200 H Shares	0.38%
7,000	1,130	139 out of 1,130 applicants to receive 200 H Shares	0.35%
8,000	1,070	139 out of 1,070 applicants to receive 200 H Shares	0.32%
9,000	1,558	212 out of 1,558 applicants to receive 200 H Shares	0.30%
10,000	6,201	877 out of 6,201 applicants to receive 200 H Shares	0.28%
20,000	5,421	1,009 out of 5,421 applicants to receive 200 H Shares	0.19%
30,000	3,691	807 out of 3,691 applicants to receive 200 H Shares	0.15%
40,000	2,469	605 out of 2,469 applicants to receive 200 H Shares	0.12%
50,000	1,567	420 out of 1,567 applicants to receive 200 H Shares	0.11%
60,000	1,352	389 out of 1,352 applicants to receive 200 H Shares	0.10%
70,000	1,071	328 out of 1,071 applicants to receive 200 H Shares	0.09%
80,000	750	242 out of 750 applicants to receive 200 H Shares	0.08%
90,000	647	219 out of 647 applicants to receive 200 H Shares	0.08%
100,000	4,429	1,559 out of 4,429 applicants to receive 200 H Shares	0.07%
200,000	4,791	2,219 out of 4,791 applicants to receive 200 H Shares	0.05%
<b>Total</b>	<b>145,681</b>	<b>Total number of Pool A successful applicants: 14,514</b>	

## Pool B

Number of H Shares applied for	Number of valid applications	Basis of allocations/ballot	Approximate percentage allotted of the total number of H Shares applied for
300,000	4,433	200 H Shares plus 2,217 out of 4,433 applicants to receive an additional 200 H Shares	0.10%
400,000	912	200 H Shares plus 609 out of 912 applicants to receive an additional 200 H Shares	0.08%
500,000	725	200 H Shares plus 588 out of 725 applicants to receive an additional 200 H Shares	0.07%
600,000	348	200 H Shares plus 326 out of 348 applicants to receive an additional 200 H Shares	0.06%
700,000	339	400 H Shares	0.06%
800,000	204	400 H Shares plus 32 out of 204 applicants to receive an additional 200 H Shares	0.05%
900,000	123	400 H Shares plus 31 out of 123 applicants to receive an additional 200 H Shares	0.05%
1,000,000	618	400 H Shares plus 209 out of 618 applicants to receive an additional 200 H Shares	0.05%
2,000,000	126	600 H Shares	0.03%
2,902,800	323	600 H Shares plus 169 out of 323 applicants to receive an additional 200 H Shares	0.02%
<b>Total</b>	<b><u>8,151</u></b>	<b>Total number of Pool B successful applicants: 8,151</b>	

*As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.*

### **COMPLIANCE WITH LISTING RULES AND GUIDANCE**

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's H Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and Stock Exchange trading fee payable.

## ***OTHERS/ADDITIONAL INFORMATION***

### ***Allocation of Offer Shares to a Close Associate of the Existing Shareholders***

The Company has sought, and the Stock Exchange has given, a consent under the paragraph 1C(2) of Appendix F1 to the Listing Rules to permit Qiyuan Hong Kong to participate in the Global Offering as a cornerstone investor subject to the conditions that:

- (a) our Company will comply with the public float requirements of Rule 19A.13A and the free float requirement under Rule 19A.13C of the Listing Rules. For details of the calculation of public float and free float of the Company, please refer to the section headed “History, Development and Corporate Structure” in this prospectus;
- (b) the Offer Shares to be subscribed by and allocated to Qiyuan Hong Kong as a Cornerstone Investor under the Global Offering will be at the same Offer Price and on substantially the same terms as the other Cornerstone Investors (including being subject to a lock-up period of six months from the Listing Date, and Qiyuan Hong Kong shall pay and settle in full the consideration for the Offer Shares before the dealing commence on the Listing Date);
- (c) no preference in allocation has been, nor will be, given to Qiyuan Hong Kong other than the preferential treatment of assured entitlement at the Offer Price under a cornerstone investment and the terms of the cornerstone investment agreement of the Qiyuan Hong Kong are substantially the same as the other cornerstone investment agreements following the principles set out in Chapters 2.3 and 4.15 of the Guide and each of the Company, the Joint Sponsors and the Overall Coordinators has provided the Stock Exchange with written confirmations in accordance with Chapters 2.3 and 4.15 of the Guide for New Listing Applicants; and
- (d) details of the allocation of the Offer Shares to Qiyuan Hong Kong in the Global Offering as a cornerstone investor are disclosed in this prospectus, and details of the allocation will be disclosed in the allotment results announcement of our Company.

Such allocations of Offer Shares to Qiyuan Hong Kong, as the close associate of the Existing Shareholders is in compliance with all the conditions under the consent given by the Stock Exchange.

For details of the allocations of Offer Shares to Qiyuan Hong Kong, please refer to the section headed “Allotment Results Details — International Offering — Cornerstone Investors” in this announcement.

## DISCLAIMERS

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer to sell or solicitation of an offer to buy, to purchase or subscribe for securities nor shall there be any sale of Offer Shares in the United States or in any other jurisdictions in which such offer or solicitation would be unlawful. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act or any state securities law of the United States. The securities may not be offered, sold, pledged, or transferred within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus dated June 15, 2026 issued by Shaanxi Micot Pharmaceutical Technology Co., Ltd. (陝西麥科奧特醫藥科技股份有限公司) for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares.*

*\* Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement upon the occurrence of any of the events set out in the paragraph headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be Friday, June 24, 2026).*

## PUBLIC FLOAT AND FREE FLOAT

Rule 19A.13A of the Listing Rules requires that where the expected market value of the Shares at the time of Listing is over HK\$6,000,000,000 but not exceeding HK\$30,000,000,000, the minimum prescribed percentage of the Shares which must be H Shares held by the public is determined at the higher of: (i) the percentage that would result in the expected market value of the H Shares held by the public to be HK\$1,500,000,000 at the time of Listing; and (ii) 15%.

Immediately after the completion of the Global Offering, an aggregate of 145,115,150 H Shares, representing approximately 43.74% of the total issued share capital of the Company upon the completion of the Global Offering will be counted towards the public float. Based on the Offer Price of HK\$18.20 per Offer Share, the expected market capitalization of the Company's H Shares would exceed HK\$6,000,000,000 and the percentage that would result in the expected market value of H shares held by the public to be HK\$1,500,000,000 at the time of Listing would be 24.84%. Therefore, the Company will be able to meet the public float requirement under Rule 19A.13A of the Listing Rules.

Rule 19A.13C(1) of the Listing Rules provides that, where a new applicant is a PRC issuer with no other listed shares at the time of listing, the portion of H shares for which listing is sought that are held by the public and not subject to any disposal restrictions at the time listing must normally (i) represent at least 10% of the total number of issued shares in the class to which H shares belong at the time of listing (excluding treasury shares), with an expected market value at the time of listing of not less than HK\$50,000,000; or (ii) have an expected market value at the time of listing of not less than HK\$600,000,000.

Immediately after the completion of the Global Offering, based on the Offer Price of HK\$18.20, except for (i) 273,685,950 Shares held by all existing Shareholders that are subject to a lock-up period of twelve months following the Listing Date under applicable PRC law; and (ii) 24,681,000 Shares held by Cornerstone Investors that are subject to a lock-up period of six months from and including the Listing Date, all remaining 33,373,400 Shares, representing 10.06% of the total Shares, will be counted toward the free float. Therefore, our Company will be able to satisfy the free float requirement under Rule 19A.13C(1)(a) of the Listing Rules.

## **COMMENCEMENT OF DEALINGS**

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Wednesday, June 24, 2026 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the section headed "Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination" in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Wednesday, June 24, 2026 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Wednesday, June 24, 2026 (Hong Kong time). The H Shares will be traded in board lots of 200 H Shares each, and the stock code of the H Shares will be 2335.

By order of the Board  
**Shaanxi Micot Pharmaceutical Technology Co., Ltd.**  
**Dr. Wang Bing**  
*Chairman, Chief Executive Officer and Executive Director*

Hong Kong, June 23, 2026

*As of the date of this announcement, the Board comprises (i) Dr. Wang Bing and Dr. Yu Weiping as executive Directors; (ii) Dr. Wang Mei, Mr. You Xiangdong, Dr. Song Gaoguang and Dr. Wang Nayi as non-executive Directors; and (iii) Dr. Xiangli Liuxu, Mr. Zhang Wenqiang and Mr. Wang Kaifeng as proposed independent non-executive Directors.*